Register new user
Fill in the details below to create your account.
suPAR® is a registered trademark of Supar Health ApS
All rights reserved © 2026
suPAR® is a registered trademark of Supar Health ApS
All rights reserved © 2026
These Terms and Conditions govern the purchase and use of products, laboratory services, software services, and related offerings made available by Supar.Health ApS through its websites, software platform, clinic network, laboratory workflows, and associated commercial channels. By purchasing, accessing, or using any Supar.Health service, you agree to be bound by these Terms and Conditions, unless a separate written agreement has been entered into between you and Supar.Health governing the relevant service.
Supar.Health ApS is a Danish company with registered address at Strandvejen 64, 2900 Hellerup, Denmark. References in these Terms and Conditions to “Supar.Health”, “we”, “us”, or “our” mean Supar.Health ApS. References to “you” mean the person or entity purchasing, accessing, or using the relevant service, whether as an individual end user, a clinic, a laboratory, or another authorized business customer.
Supar.Health operates as both a clinical diagnostics provider and a digital health platform. Our services may include the sale and coordination of suPAR testing services, the supply of sample collection kits and associated logistics, central or decentralized laboratory analysis, secure digital reporting, software subscriptions, hosting of user data, reporting engines, application programming interface access, and related bioinformatic or analytical tools.
The Supar.Health service environment supports three principal categories of customers. The first category is individual patients or end users. The second category is clinics, healthcare practices, or other medical organizations purchasing tests, software functionality, or associated laboratory services. The third category is laboratories and laboratory organizations purchasing access to our LIMS, reporting, or platform infrastructure and, in certain cases, reagent kits or related sample processing products.
Certain parts of the overall Supar.Health ecosystem are clinically regulated, while others are currently provided in research-use or investigational mode. The suPAR assay itself and the reported suPAR concentration are provided as clinically regulated outputs where performed within the applicable CE-IVD framework and associated laboratory procedures. By contrast, certain advanced software features, reporting layers, bioinformatic functions, and analytical interpretations available through the platform are currently made available for research, informational, health optimization, or investigational use only, pending completion of further regulatory processes. These distinctions will be identified where relevant in the platform, in supporting documentation, or in the applicable product description.
Patients
A patient may purchase a suPAR test service directly from Supar.Health, including through our website or an affiliated clinic or partner flow. Where a patient purchases a test directly from Supar.Health, the purchase will ordinarily be fulfilled through a participating clinic selected by the patient. In such cases, the patient’s payment to Supar.Health operates as payment for a redeemable test service, typically implemented through a voucher or equivalent booking mechanism that is redeemed with the chosen clinic. The participating clinic will perform the relevant patient-facing service, including sample collection and, where applicable, clinical interpretation within that clinic’s own medical responsibility.
Patients may also subscribe directly to premium software functions made available through the Supar.Health platform. Such premium services may include secure hosting of user data, longitudinal result storage, advanced bioinformatic interpretation, dashboard functions, and related premium digital features. Where such services are offered on a subscription basis, they may be billed monthly or at such other recurring interval as specified at the time of purchase.
Clinics
Clinics may purchase suPAR test kits, laboratory analysis services, return shipping labels, software subscriptions, hosted access to the Supar.Health platform, reporting tools, and related services. Clinics may use the platform to manage patient workflows, receive or review test results, and access premium software functions, subject to the permissions, licensing, and regulatory scope applicable to the services selected.
Laboratories
Laboratories may purchase access to Supar.Health LIMS functionality and related reporting tools, including access via API or through the Supar.Health platform interface. Laboratory customers may also, in certain cases, purchase reagent kits, sample collection materials, and other operational products necessary to perform suPAR analysis or associated biomarker workflows. Laboratory subscriptions will generally include a platform fee based on users and functionality, hosting charges where applicable, and a per-report or per-test fee for generated outputs.
Where a patient purchases a suPAR test service directly from Supar.Health, the order shall be deemed accepted once payment has been successfully completed and confirmation has been issued. The test service is then fulfilled through a selected participating clinic, and the clinic may receive a fee for sample collection, consultation, or related patient service as part of the commercial arrangement. Supar.Health retains the portion of the purchase price corresponding to the products, platform, laboratory analysis, logistics, and other agreed service components.
Any physical kit required for the patient service may be shipped either directly to the selected clinic or, where the chosen workflow allows, to another delivery destination approved by the clinic or indicated during the purchase process. Shipping costs are calculated per purchase and will be presented at or before checkout. Unless expressly stated otherwise, the patient is responsible for any import VAT, customs duty, local taxes, or similar charges arising in connection with international delivery. Supar.Health is not responsible for such charges and shall not be liable for delays, withholding, or additional costs arising from customs procedures or local import requirements.
Where a patient subscribes to premium software services, such services may renew automatically on a monthly or other recurring basis unless cancelled in accordance with the cancellation terms communicated at the time of purchase or made available within the user account.
Where a patient purchases products or services from Supar.Health as a consumer through distance selling channels, the patient may have statutory withdrawal rights in accordance with applicable consumer law. Unless a statutory exception applies, a patient may withdraw from an eligible purchase within fourteen days.
For physical goods, including unopened and unused kits or related materials that are capable of being returned in suitable condition, the withdrawal period shall run from the date of receipt. Returned goods must be unused, undamaged, and returned in a condition suitable for inspection and, where possible, resale. Unless otherwise required by law or expressly agreed by Supar.Health, the patient shall bear the cost of return shipment.
For diagnostic test services purchased directly from Supar.Health and fulfilled through a clinic voucher or equivalent mechanism, the patient may cancel and receive a full refund during the withdrawal period provided that no clinic booking has been confirmed, no kit has been dispatched, no laboratory processing has been initiated, and no part of the service has otherwise begun at the patient’s request. If the patient expressly requests that the service begin during the withdrawal period, including by confirming clinic redemption, requesting shipment, or initiating related processing steps, Supar.Health reserves the right to charge a proportionate amount corresponding to the part of the service already performed and to deduct any non-recoverable logistics or administrative costs already incurred. Once the relevant diagnostic service has been fully performed, any statutory withdrawal right shall cease to apply to the extent permitted by law.
For premium software subscriptions purchased directly by patients, the patient may cancel within the applicable withdrawal period unless the patient has expressly requested immediate access or activation and acknowledged that the right of withdrawal may be lost once performance has begun or the digital service has been supplied in accordance with applicable law. After the expiry of any applicable withdrawal period, subscription fees are non-refundable except where mandatory law provides otherwise.
Clinics may purchase test kits, laboratory analyses, shipping labels, software subscriptions, hosted storage, premium analytical functions, onboarding services, and related professional services from Supar.Health. Orders are binding once accepted by Supar.Health, whether through the website, a written quotation, an onboarding agreement, or another documented commercial process.
Shipping costs for kits, labels, or related materials are calculated at checkout or otherwise stated in the applicable quotation or commercial agreement. The clinic is solely responsible for any VAT, import duty, customs charge, local tax, or equivalent governmental fee associated with the purchase, importation, or use of such products and services, unless otherwise expressly agreed in writing.
A clinic subscription may include one or more of the following commercial elements: a one-time onboarding or setup fee, recurring subscription fees based on the number of users or enabled modules, fees for secure hosting of patient or clinic data, fees for premium software functionality, and per-test or per-report fees where applicable.
Unless otherwise agreed in writing, clinic subscriptions shall commence with a minimum binding term of six months. Upon expiry of the initial six-month term, the subscription shall renew automatically for successive renewal periods unless terminated in writing by either party with at least thirty days’ notice prior to the end of the then-current term. Supar.Health reserves the right to revise pricing or service structures on reasonable prior notice, provided that any already committed fixed term shall remain governed by the terms agreed for that term unless otherwise expressly stated.
For clinics outside the European Union, the regulatory classification and permitted marketing scope of the offered products and software may differ from the position applicable within the EU. In particular, while the suPAR assay may be supplied within the CE-IVD framework in relevant European markets, the same assay or associated service components may in other jurisdictions, including the United States, be offered only for Research Use Only and not for clinical diagnostic use, unless and until additional regulatory clearance or approval has been obtained. The clinic is responsible for ensuring that its use of any purchased product or software complies with local law, local regulatory requirements, and the intended use designation applicable in the relevant jurisdiction.
Samples submitted for analysis must meet the applicable technical, pre-analytical, handling, storage, packaging, transport, labeling, and timing requirements specified by Supar.Health, the relevant laboratory protocol, and any applicable instructions for use. Proper sample quality and integrity are essential to enable valid and reliable analysis.
If a sample arrives damaged, degraded, mislabeled, contaminated, improperly stored, delayed beyond acceptable limits, or otherwise unsuitable for analysis, or if it has not been collected, handled, or shipped in accordance with the applicable protocol, the sample may be designated as failed or rejected. In such circumstances, Supar.Health shall not be responsible for replacement sampling, replacement materials, or any associated patient-facing or operational costs incurred by the clinic, except to the extent that the sample failure is directly attributable to a fault for which Supar.Health is legally responsible.
A failed sample may give rise to additional fees, including fees for administrative handling, repeat logistics, or repeat analysis, depending on the circumstances and the applicable commercial arrangement. In certain cases, and at Supar.Health’s sole discretion or where expressly agreed, all or part of the analysis charge may be credited, particularly where the failed sample cannot reasonably be attributed to the clinic, patient handling, or transport conditions outside Supar.Health’s control. Any such credit shall be a commercial adjustment and shall not constitute an admission of liability.
Where a patient-facing service is performed through a clinic, the clinic remains solely responsible toward the patient for sample collection quality, protocol adherence, and management of any failed sample event, including re-sampling, patient communication, and any associated clinical or service obligations.
Laboratory customers may purchase access to Supar.Health LIMS functionality, software modules, API integrations, report-generation tools, and associated hosting services. Such services may be provided as text-based API outputs for integration into an existing laboratory information system or via the Supar.Health platform itself.
Laboratory purchases may also include, where offered, access to reagent kits supplied by ViroGates or other designated suppliers, sample draw kits, calibration materials, controls, and related laboratory consumables. In addition to any product charges, a laboratory customer’s subscription will ordinarily include a platform subscription fee calculated according to the number of users, features enabled, or organizational scope of the implementation, together with hosting fees and usage-based charges, including charges per generated test report or analytical output where applicable.
Unless otherwise agreed in writing, laboratory subscriptions shall commence with a minimum binding term of six months. Upon expiry of the initial six-month term, the subscription shall renew automatically for successive renewal periods unless terminated in writing by either party with at least thirty days’ notice prior to the end of the then-current term.
The laboratory remains responsible for ensuring that any use of purchased products, software outputs, or reports is consistent with the applicable intended use, accreditation standards, laboratory regulations, and the legal framework governing the relevant territory.
All fees are payable in the currency and by the payment method specified at the time of order, invoicing, or subscription signup, unless otherwise agreed in writing. Supar.Health reserves the right to require advance payment for products, subscriptions, kits, analyses, onboarding, or other services.
Recurring software subscriptions shall renew automatically for successive billing periods unless cancelled before the next renewal date in accordance with the applicable cancellation process. Failure to pay any invoice, subscription amount, or other due charge may result in suspension of access to the relevant services, delayed processing of orders, withholding of reports, or termination of the affected account or agreement, subject to applicable law and any mandatory professional obligations.
Unless otherwise stated, all prices are exclusive of shipping, customs costs, VAT, import taxes, local duties, or other governmental charges. Such amounts shall be borne by the purchasing customer.
Where Supar.Health arranges the shipment of kits, labels, or related materials, delivery times are estimates only and not guaranteed, unless expressly stated otherwise in writing. Risk in physical goods shall pass in accordance with the agreed delivery terms or, if no specific delivery term has been agreed, when the goods are delivered to the carrier or made available to the customer, as appropriate under the transaction structure.
Customers are responsible for providing accurate shipping details and for ensuring that imported goods may lawfully be received in the relevant jurisdiction. Supar.Health shall not be liable for customs delays, seizure, additional local charges, or delivery disruption caused by incorrect delivery information, local import restrictions, force majeure, or third-party carrier failures.
Where a patient purchases a test service fulfilled through a participating clinic, the clinic remains responsible for the patient-facing medical relationship, including sample collection, the exercise of clinical judgment, interpretation of results in the broader medical context, and compliance with applicable medical record and consent obligations. Supar.Health may provide products, central laboratory analysis, digital infrastructure, and reporting support, but the existence and scope of medical responsibility depends on the specific service model and the role of the participating healthcare provider.
Where a sample fails or is rejected in a patient-facing clinic workflow, the operating clinic bears sole responsibility toward the patient for handling that event, including any re-sampling, communication, and follow-up obligations, except where mandatory law imposes non-excludable responsibility on another party.
Where Supar.Health itself operates or oversees a laboratory function, it does so within the scope of the applicable laboratory and regulatory framework. Where a laboratory or clinic uses the Supar.Health platform independently, that organization remains responsible for its own legal compliance, data governance, medical responsibility, and any patient communication or clinical use of the outputs, except to the extent that responsibility is explicitly assumed by Supar.Health in a separate written agreement.
Supar.Health distinguishes between regulated diagnostic outputs and software-enabled outputs that are presently provided in investigational, informational, or Research Use Only mode. The suPAR test result itself, when generated through the applicable CE-IVD assay and corresponding laboratory workflow, is intended as a clinically regulated biomarker result within the scope of the relevant assay and laboratory process. However, parts of the reporting engine, dashboard functionality, advanced bioinformatic interpretation, risk stratification layers, biological age estimates, community-derived comparison models, and certain algorithmic or longitudinal features currently operate outside final medical-device certification and are therefore provided for research, information, wellness, or decision-support purposes only, and not as independently certified medical device outputs.
Such RUO or investigational outputs must not be used as the sole basis for diagnosis, treatment, emergency decisions, prescribing, or other medical interventions. They are intended to supplement, and not replace, professional medical evaluation and clinically validated diagnostic information.
Subject to compliance with these Terms and Conditions and payment of all applicable fees, Supar.Health grants the relevant customer a limited, non-exclusive, non-transferable, non-sublicensable right to access and use the software platform, user interface, reporting engine, API, and associated functionality solely for the customer’s internal and permitted use in accordance with the purchased service.
The platform, source code, software architecture, analytical methods, interfaces, databases, visualizations, reports, trademarks, and all related intellectual property rights remain the exclusive property of Supar.Health or its licensors. The customer shall not copy, reverse engineer, modify, decompile, extract, republish, resell, or otherwise exploit the platform or its components except to the extent expressly permitted by mandatory law or by a separate written agreement.
Use of the Supar.Health services involves the processing of personal data, including health data. Such processing is governed by the applicable Privacy Policy, data processing agreements, consent flows, and, where relevant, clinic or laboratory onboarding documents. Patients retain the rights granted to them by applicable data protection law in relation to their identifiable personal data. Clinics and laboratories remain responsible for the lawfulness of their own processing where they act as independent data controllers.
Supar.Health does not claim ownership of a patient’s personal data as such. However, where data has been lawfully anonymized in such a way that no individual may be identified directly or indirectly, Supar.Health may retain and use such anonymized data for research, development, analytics, software improvement, bioinformatic model training, artificial intelligence development, and commercial purposes, including collaboration, licensing, and platform-wide improvement. This principle is further described in the Privacy Policy and any applicable separate consent documentation.
Supar.Health may from time to time modify, improve, update, suspend, or discontinue parts of its products or software services in order to maintain security, stability, regulatory compliance, or technical performance. This may include updates to user interfaces, functionality, pricing structures, subscription plans, API formats, data models, workflows, and report layouts.
We will seek to provide reasonable notice where changes materially affect paid services. However, we reserve the right to implement urgent modifications without prior notice where necessary to address security risks, legal requirements, system integrity, or patient safety concerns.
Unless otherwise agreed in writing, subscriptions continue for the minimum term and any subsequent renewal period unless cancelled in accordance with the applicable notice provisions. One-time purchases, including test purchases, kit purchases, or onboarding fees, are non-cancellable once the relevant order has been accepted and processing, shipment, booking, or provisioning has begun, except where mandatory consumer law requires otherwise.
Supar.Health may suspend, revoke, or terminate access to the platform and related services with immediate effect upon breach by a clinic, laboratory, or other business customer. This includes, without limitation, breach of payment obligations, misuse of regulated or RUO outputs, unlawful use, unauthorized access, misuse of patient data, cybersecurity or confidentiality failures, regulatory non-compliance, misuse of the reporting environment, or any conduct that may expose Supar.Health, patients, clinics, laboratories, or other users to legal, safety, regulatory, or operational risk.
Such immediate suspension, revocation, or termination shall not affect accrued payment obligations, confidentiality obligations, intellectual property protections, liability limitations, or any provision intended by its nature to survive termination.
Supar.Health will use reasonable professional care in providing its products and services. However, except to the extent that a specific warranty is required by law or expressly set out in writing, the software platform and its non-regulated features are provided on an “as is” and “as available” basis. We do not warrant that the platform will be uninterrupted, error-free, or suitable for every user purpose, workflow, or regulatory environment.
Clinical laboratory analysis is performed in accordance with the applicable assay, laboratory procedures, and quality systems, but biological and technical variability remains inherent in laboratory medicine. Except where prohibited by law, Supar.Health disclaims warranties of merchantability, fitness for a particular purpose, uninterrupted availability, and non-infringement in relation to the software environment and other non-regulated digital features.
To the fullest extent permitted by applicable law, Supar.Health shall not be liable for any indirect, incidental, special, consequential, punitive, or purely economic loss, including loss of profit, loss of business opportunity, loss of reputation, or loss of data, arising out of or in connection with the use of the services, except where such limitation is prohibited by mandatory law.
To the extent permitted by law, Supar.Health’s total aggregate liability arising under or in connection with these Terms and Conditions shall not exceed the amount paid by the relevant customer to Supar.Health for the specific product or service giving rise to the claim during the twelve-month period preceding the event giving rise to liability. Nothing in these Terms and Conditions shall exclude or limit liability that cannot lawfully be excluded, including liability for fraud, fraudulent misrepresentation, or death or personal injury caused by negligence where such exclusion is not permitted.
These Terms and Conditions shall be governed by and construed in accordance with the laws of Denmark, without regard to conflict-of-law principles. Any dispute arising out of or in connection with these Terms and Conditions shall be subject to the jurisdiction of the Danish courts, unless mandatory consumer protection law provides otherwise.
Supar.Health may amend these Terms and Conditions from time to time in order to reflect changes in law, regulatory position, product design, pricing models, technical infrastructure, or commercial structure. The most recent version will be made available through the website or platform. Where material changes affect ongoing subscriptions or established customer relationships, we will provide reasonable notice in accordance with applicable law.
V1.260326.1025
Date: 26.03.2026
Supar.Health is committed to protecting your privacy and to handling your personal data, including health-related information, with a high degree of care, confidentiality, and transparency. This Privacy Policy explains how Supar.Health collects, uses, stores, shares, and otherwise processes personal data in connection with the Supar.Health platform, its diagnostic services, and its related digital health infrastructure. It also explains your rights in relation to such processing and the legal framework under which that processing takes place.
This Privacy Policy is intended to reflect and support compliance with applicable European Union and Danish legislation, including the General Data Protection Regulation (EU) 2016/679 (“GDPR”), the Danish Data Protection Act, the Danish Health Act (Sundhedsloven), the Danish rules on medical record keeping, and other applicable legal and regulatory requirements relevant to clinical diagnostics, digital health services, and laboratory operations.
Supar.Health ApS, CVR no. 41298790, is a clinical diagnostics provider and digital health platform operator established in Denmark. Supar.Health develops and offers biomarker-based health testing services, including suPAR testing performed using CE-IVD assays, and provides a software platform through which test results, clinical data, and certain health-related information may be viewed, managed, and, where relevant, interpreted in a structured digital environment.
Our registered address is Strandvejen 64, 2900 Hellerup, Denmark. Questions relating to this Privacy Policy or to our processing of personal data may be directed to us using the contact details made available on our website and in our contractual documentation.
Depending on the specific service model and workflow involved, Supar.Health may act either as an independent data controller, for example in relation to operation of its own platform environment and the processing of anonymized data for research and development purposes, or as a data processor acting on behalf of a clinic or other healthcare provider. In certain cases, role allocation may depend on the underlying contractual arrangement and the medical responsibility associated with the service in question.
This Privacy Policy applies to the processing of personal data that takes place when you interact with Supar.Health as a patient, end user, clinic representative, laboratory user, website visitor, or other relevant party in connection with our services. It applies to processing carried out through our website, our software platform, our communications with you, our diagnostic workflows, and any related clinical, technical, scientific, or administrative processes that form part of the Supar.Health service environment.
In some contexts, additional notices, consents, or service-specific privacy terms may be provided, for example in connection with specific research activities, genetic testing, biobank participation, or certain clinic-specific workflows. Where such supplementary notices are provided, they are intended to complement this Privacy Policy and should be read together with it.
The Supar.Health platform is designed as a regulated, role-based clinical and digital infrastructure supporting several different categories of users. These typically include individual end users or patients, clinics that offer or interpret testing services and maintain the underlying medical relationship with the patient, laboratories that process biological samples and generate test results, and Supar.Health itself in its capacity as platform provider, product supplier, and in some contexts laboratory operator.
The legal and operational responsibilities of these parties are not identical. In many cases, the clinic with responsibility for the patient relationship, medical interpretation, and record-keeping will act as the primary data controller for the identifiable clinical data processed in connection with a given patient. Laboratories may act either as processors acting on behalf of a clinic or, in certain workflows, as independent controllers where they themselves assume medical responsibility for issuing and reporting results. Supar.Health may also, depending on the service model, act as an independent controller for certain platform-related and anonymized data processing activities, while acting as a processor or infrastructure provider in relation to identifiable clinical information processed on behalf of clinics.
Because of this multi-actor model, access to data within the platform is strictly controlled through user-role governance, permission structures, and technical segregation. A clinic does not gain access to all users of the platform, but only to those patients with whom it has an established relationship and for whom the necessary permissions and legal basis exist. Likewise, laboratories and administrative users are restricted to the information necessary for their specific role and function.
In the course of providing our services, Supar.Health may process a broad range of personal data and health-related information. This may include ordinary personal data such as your name, date of birth, email address, telephone number, address, and, where legally necessary, national identification information such as a CPR number. We may also process information concerning your use of our platform, such as log-in data, system activity, device information, IP address, and other technical information relevant to maintaining platform integrity, security, and functionality.
Where you use our clinical or laboratory services, we may process health-related data including biomarker results, such as suPAR measurements expressed in ng/mL, medical history, symptoms, medication information, lifestyle factors, referral information, clinician notes, and other metadata relevant to the interpretation of your result. We may also process information associated with biological samples, such as sample identifiers, collection details, chain-of-custody information, and processing status.
In addition, we may process communications exchanged with you or with clinics, laboratories, and other authorized parties in connection with support, clinical coordination, quality assurance, or service administration. We also retain records relating to user consents, preferences, and access permissions, including any permissions granted by a patient to a clinic in relation to read and write access to data within the platform.
Supar.Health processes personal data only for specified and legitimate purposes and only to the extent necessary in relation to those purposes. The central purpose of processing is the provision of clinical diagnostic services and supporting digital infrastructure. This includes receiving and registering requests for testing, processing samples, generating laboratory results, presenting results through the platform, facilitating clinical reporting, and enabling authorized healthcare professionals to interpret and act upon the results where relevant.
Personal data is also processed to maintain secure user accounts, support the functioning of the platform, administer clinic and laboratory workflows, provide customer and technical support, monitor quality, ensure traceability and auditability, and comply with legal and regulatory requirements applicable to healthcare, diagnostics, and medical documentation.
In addition, Supar.Health may process data for scientific, analytical, and developmental purposes, including the improvement of diagnostic methods, the development of software functionality, the validation of reporting engines, the refinement of bioinformatic models, and broader research and innovation activities related to chronic inflammation, biomarker interpretation, and precision health. Where such activities involve personal data, they are carried out only under an appropriate legal basis and with applicable safeguards. Where such activities rely on data that has been anonymized in a manner that removes the possibility of direct or indirect identification, such data may be used on an ongoing basis for research, statistical, technical, and commercial development purposes.
Supar.Health only processes personal data where a valid legal basis exists under the GDPR and, where relevant, applicable Danish healthcare law. In the context of core diagnostic services, personal data is generally processed because such processing is necessary in order to perform a contract or requested service, and because the processing of health data is necessary for the purposes of preventive medicine, medical diagnosis, the provision of healthcare, or the management of healthcare systems and services, in accordance with Article 6(1)(b) and Article 9(2)(h) of the GDPR, together with the relevant provisions of Danish law.
Certain forms of processing are also carried out because they are necessary in order to comply with legal obligations, including obligations relating to medical record keeping, traceability, quality assurance, and reporting to public authorities where required. In addition, some processing may be based on Supar.Health’s legitimate interests, for example in maintaining the security, integrity, and functionality of the platform, conducting internal quality control, preventing misuse, and improving service performance, provided always that such interests are balanced against the rights and freedoms of the individuals concerned.
Where optional services or secondary uses are involved, such as certain research activities, marketing communications, genetic testing, biobank participation, or specific forms of AI or model training involving personal data, processing will be based on consent or on another specific legal basis where appropriate. Any such consent must be specific, informed, voluntary, and capable of withdrawal at any time, without affecting the lawfulness of prior processing carried out before that withdrawal.
A fundamental part of the Supar.Health data governance model is the distinction between identifiable data, pseudonymized data, and anonymized data. Identifiable data refers to information that directly identifies you or that can readily be linked to you, such as your name, contact details, personal identifier, or linked clinical record. Pseudonymized data refers to data in which direct identifiers have been replaced by codes or indirect identifiers, but where re-identification remains possible through the use of additional information. Under the GDPR, pseudonymized data remains personal data and is treated accordingly.
Anonymized data, by contrast, refers to data that has been irreversibly processed in such a way that no individual can be identified directly or indirectly by Supar.Health or by any other party using means reasonably likely to be used. Only where this threshold has been met is the data considered no longer to constitute personal data under European data protection law.
Supar.Health may use anonymized data derived from platform use, biomarker testing, associated metadata, and system-level analysis for research, statistical evaluation, product development, clinical validation, artificial intelligence development, bioinformatic model training, platform optimization, and commercial purposes, including collaboration and licensing activities. Such use is contingent upon the data having been transformed into a genuinely anonymous form. Supar.Health does not claim ownership of your personal data as such; however, where data has been rendered anonymous in accordance with applicable law, Supar.Health may retain and use that anonymous data independently and on an ongoing basis.
The Supar.Health platform is designed to allow patients to maintain meaningful control over identifiable personal data within their own digital health environment, subject always to legal and clinical constraints. A patient may, for example, be associated with one or more clinics and may have the ability to determine whether a given clinic is permitted to read from or write to the patient’s record within the platform. This permission structure supports a controlled and role-based sharing model that is intended to reflect both patient autonomy and the need for medically responsible access.
At the same time, not all forms of control are absolute. Where a clinic or laboratory is subject to statutory obligations under Danish healthcare law, including obligations relating to journalføring and retention of medical records, certain identifiable data may need to be retained even if a patient requests deletion. In those cases, the right to erasure may be limited by law. Supar.Health will, however, seek in all cases to ensure that personal data is processed only to the extent necessary and that patients are informed clearly about the legal basis and limitations applicable to such processing.
Supar.Health treats personal and health-related information as confidential and does not sell identifiable personal data. Personal data may be disclosed only where this is necessary and legally justified. This may include disclosure to clinics, physicians, healthcare professionals, laboratory personnel, technical service providers, hosting providers, software infrastructure providers, payment processors, regulatory authorities, and other parties whose involvement is necessary in order to deliver the service, support a lawful clinical workflow, maintain the platform, or comply with legal obligations.
Where third parties process data on our behalf, we require them to do so under appropriate contractual safeguards, including data processing agreements where applicable, and only in accordance with documented instructions and confidentiality obligations. Where data is shared with a clinic or laboratory acting as an independent controller, that party is responsible for its own lawful processing in accordance with the applicable healthcare and data protection framework.
Where anonymized datasets are used in scientific collaboration, technical development, or commercial partnerships, such disclosure may take place without involving personal data, provided that the data has first been anonymized to the standard required under applicable law.
Where personal data is transferred outside the European Union or the European Economic Area, Supar.Health will ensure that appropriate safeguards are in place in accordance with Chapter V of the GDPR. This may include reliance on an adequacy decision issued by the European Commission, the use of the European Commission’s standard contractual clauses, or other legally recognized safeguards. In each case, we seek to ensure that transferred data receives a level of protection essentially equivalent to that guaranteed within the EU.
Supar.Health applies a combination of technical and organizational measures designed to protect personal data against unauthorized access, loss, misuse, alteration, or unlawful disclosure. These measures include encryption of data in transit and at rest, access control mechanisms based on user roles and necessity, logging and monitoring of data access, secure hosting environments, segregation of environments, incident response procedures, and continuous review of system security.
Because the platform processes health-related information and supports regulated diagnostic workflows, security is treated as a core compliance requirement rather than merely a technical feature. Access to identifiable data is restricted to persons with a legitimate need to know, and internal governance measures are intended to ensure that no user or organizational actor is able to access broader datasets than required for their function.
Supar.Health retains personal data only for as long as necessary for the purposes for which it was collected and processed, unless a longer retention period is required by law. In the clinical context, medical records and related diagnostic data may need to be retained for the period mandated by Danish healthcare legislation and associated record-keeping requirements. This means that some data cannot be erased upon request where legal retention duties apply.
Account information and platform-level data may be retained for as long as the user relationship exists and for a reasonable period thereafter where necessary for legal, audit, or operational purposes. Where possible and appropriate, data that is no longer required in identifiable form may be deleted, restricted, or anonymized. Once data has been anonymized in a legally valid and irreversible manner, it may be retained indefinitely for scientific, technical, statistical, and commercial development purposes, because it no longer constitutes personal data.
Under the GDPR and applicable Danish law, you have a number of rights in relation to the personal data concerning you. These include the right to obtain access to your data, the right to request rectification of inaccurate information, the right in certain circumstances to request erasure, the right to request restriction of processing, the right to data portability for data processed by automated means on the basis of consent or contract, and the right to object to certain forms of processing based on legitimate interests.
Where processing is based on consent, you also have the right to withdraw that consent at any time. Such withdrawal does not affect the lawfulness of the processing carried out before consent was withdrawn. It should be noted, however, that these rights apply only in relation to personal data. They do not extend to data that has been anonymized in such a way that it can no longer be linked to you.
If you wish to exercise any of your rights, you may contact Supar.Health using the contact details provided on our website or in our contractual documentation. We may request reasonable proof of identity before responding to such requests.
If you have concerns regarding the way in which Supar.Health processes your personal data, we encourage you to contact us first so that we may seek to resolve the matter promptly and appropriately. You also have the right to lodge a complaint with the Danish Data Protection Agency, Datatilsynet, if you believe that your personal data has been processed in breach of applicable law. Where a matter relates specifically to the provision of healthcare services or medical responsibility, you may also have rights to raise concerns with the relevant Danish health authorities.
Supar.Health may update this Privacy Policy from time to time in order to reflect changes in legal requirements, technical infrastructure, service models, or data processing practices. Where material changes are made, we will take reasonable steps to bring those changes to your attention through the platform, by email, or by other appropriate means. The most recent version of this Privacy Policy will always be made available through our website and platform environment.
V1.260326.1015
Date: 26.03.2026
The information made available on this website, including any text, graphics, visualizations, result explanations, biological age estimates, health optimization content, and software-generated interpretations, is provided for general informational, educational, and service-related purposes only. It is not intended to constitute medical advice, medical diagnosis, or treatment, and it must not be relied upon as the sole basis for clinical decision-making, prescribing, emergency assessment, or the management of any disease or health condition.
Supar.Health provides access to suPAR testing services and related digital reporting tools. The suPAR biomarker assay used in the relevant clinical workflow is a clinically validated CE-IVD assay, and the reported suPAR concentration generated through that assay and laboratory process constitutes the regulated laboratory result. However, certain additional features made available through the Supar.Health platform, including software-based interpretations, reporting layers, longitudinal comparisons, biological age estimates, algorithmic analytics, and other advanced bioinformatic functions, are currently provided for informational, wellness, research, or decision-support purposes only. These software-enabled features are not, at the present time, independently certified as CE-IVDR medical device outputs and must therefore not be interpreted as standalone diagnostic conclusions.
Any interpretation of a suPAR result must take place in the context of the individual’s full clinical picture, including symptoms, history, medication use, comorbidities, and other relevant examinations and laboratory findings. A suPAR result, whether low, intermediate, or elevated, does not by itself establish the presence or absence of any disease, nor does it guarantee future health outcomes. Although suPAR is a well-studied biomarker associated with immune activation, inflammation, prognosis, and risk stratification across a broad range of clinical conditions, it should always be assessed in conjunction with appropriate medical judgment and, where relevant, consultation with a licensed healthcare professional. The current website likewise states that the website information should not be used as the sole basis for diagnosis or treatment and that results should be assessed together with medical advice and other examinations. Any references on this website to chronic inflammation, disease risk, health optimization, biological age, aging rate, resilience, or similar constructs are intended to communicate general scientific or health-related context and should not be understood as constituting a diagnosis, prognosis, or individualized treatment recommendation unless expressly stated otherwise in a clinically regulated setting. Biological age calculations and related interpretive models are based on statistical associations, internal modeling, published literature, and evolving datasets, and are inherently estimative in nature. Such outputs may be useful as contextual tools for understanding patterns in biomarker data, but they remain subject to scientific and regulatory development and must not be treated as definitive medical determinations. The current public disclaimer similarly states that biological age is an estimate and that these interpretive tools are intended for research and informational purposes only.
Nothing on this website is intended to replace consultation with a physician or other qualified healthcare professional. You should not ignore, postpone, or discontinue seeking medical advice, diagnosis, or treatment on the basis of information presented on this website or through any non-regulated software feature of the platform. If you are pregnant, undergoing treatment, have an existing diagnosis, are experiencing symptoms, or have concerns regarding your health, you should consult an appropriately qualified healthcare professional. This is consistent with the present public website disclaimer, which advises users to seek physician input in such circumstances.
For patients whose testing is arranged through a participating clinic, the clinic remains responsible for the patient-facing medical relationship, including any clinical evaluation, communication of findings, and interpretation of results in the broader medical context. Where services are provided through partner clinics, laboratories, or other healthcare organizations, the scope of medical responsibility may therefore differ depending on the operational model and applicable legal framework.
For customers or users located outside the European Union, the regulatory classification, intended use, and lawful availability of specific Supar.Health products, reports, software functions, or associated services may differ by jurisdiction. In particular, certain products or software-enabled features may be available only for Research Use Only in specific markets unless and until local regulatory clearance or approval has been obtained. Users and professional customers outside the EU are responsible for ensuring that any use of Supar.Health products or services complies with applicable local law and regulatory requirements.
By using this website and the associated platform, you acknowledge that the Supar.Health ecosystem contains both clinically regulated diagnostic components and additional informational or research-oriented digital features, and you agree that any non-regulated outputs are used only within their stated intended purpose. Where further detail is required, users should consult the applicable Terms & Conditions, Privacy Policy, product documentation, and instructions provided in connection with the relevant service.